No Data
Zejing Pharmaceutical 2024 annual results forecast
Zhejiang Jingxin Pharmaceutical (688266.SH): Expected net loss in 2024 is between 0.11 billion yuan and -0.16 billion yuan.
On January 17, Gelonghui reported that Zhejing Pharmaceutical (688266.SH) announced that (1) after preliminary calculations by the financial department, it is expected to achieve revenue of 517.93 million yuan to 549.88 million yuan for the fiscal year 2024, representing an increase of 34.03% to 42.30% compared to the same period last year. (2) The company expects to achieve a Net income attributable to owners of the parent company ranging from -163.9 million yuan to -109.83 million yuan for fiscal year 2024, a decrease in the loss compared to the same period last year by 114.6827 million yuan to 168.7527 million yuan. (3) The company expects...
China Galaxy Securities: A review of the fifth set of standards on the Star has significantly boosted investment in the pharmaceutical industry.
Future reforms in diversified payment for commercial insurance are expected to bring marginal improvements from a policy perspective, and there are good long-term investment opportunities in pharmaceutical innovation and related industries.
Jianghai Securities: The enthusiasm for DLL3 drug development is increasing, and the prospects for domestic ADC drugs are broad.
As the recognition of domestic Innovative Drugs in the international market continues to rise, companies with potential for international cooperation and expansion are expected to further explore market opportunities.
Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.
DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.
Zelgen Biopharma Gets Nod to Trial Cancer Drug Combination
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%
